PT376 – Ketamine and Psychedelic-Assisted Therapy as Employee Benefits

December 6, 2022
Featuring: Sherry Rais

In this episode, David interviews Sherry Rais: Executive Director of the Boston Psychedelic Research Group, Grants Manager for CIIS, and CEO/Co-Founder of Enthea.

Subscribe Share

In this episode, David interviews Sherry Rais: Executive Director of the Boston Psychedelic Research Group, Grants Manager for CIIS, and CEO/Co-Founder of Enthea.

Enthea is a benefit plan administrator that provides health plan benefit riders and single case agreement services for psychedelic healthcare with a provider network including certified and credentialed Ketamine-Assisted Therapy (KAT) and Psychedelic-Assisted Therapy (PAT) practitioners. In other words, if a company wants to offer psychedelic-assisted therapy as a benefit for their employees, Enthea makes this possible (and affordable). Their first client was the very psychedelically-minded Dr. Bronner’s Magic Soaps, and they’ve just announced the signings of three new clients that you may not expect to provide KAP to their employees: Daybreaker, Tushy, and Guinn Partners. Their goal is to have 100,000 covered lives in 40 cities by the end of 2023, and, alongside the guidance of MAPS, hopefully roll out MDMA-assisted therapy in Q2 of 2024. 

Rais talks about Enthea’s process, costs, and goals; her Ismaili religion; her nomadic, marathon-running life; her experience sleeping on the streets of Toronto at 16 and her need to help the less-fortunate; how her most powerful psychedelic experience was watching someone else transform; and why companies are suddenly interested in these emerging therapies.

Notable Quotes

“For me, the most powerful psychedelic experience I had was actually in a situation where I was sitting with someone else and saw this person transform in front of me. That was two years ago and that person; I still see the effects of that experience on that person’s life and how much he’s changed from this one experience, and I’ve never seen anything like it. It was the most beautiful thing I’ve ever witnessed.”

“I think you and I know that these medicines work, and we also know that they cost way more than $500, and immediately, that tells me there’s an equity crisis in the ecosystem; that we’ve finally found medicines that may be able to help millions of people that are suffering from a variety of issues, and there’s this huge barrier and its cost. So the goal of Enthea is to solve that problem by making these medicines affordable.”

“The fact that you have a plan that doesn’t cover mental health is very telling of the landscape and the culture in America today and why you’ve made the case for me on why Enthea is needed. Because if this doesn’t happen, when will people get access? They’ll continue waiting and waiting and waiting that their primary insurance provider covers this.”


Minority Trip Report Podcast: 1-7 – Sherry Rais: Social Impact, Psychedelic Therapy as Employee Benefit, and Finding Strength as a Female CEO

Psychedelics Today: PT364 – Burning Man, Psychedelic Maturity, and Radical Hope, featuring: Jamie Wheal Dr. Bronner’s to Provide Psychedelic-Therapy as Employee Healthcare Benefit Ketamine-Assisted Therapy, A Light In The Dark Laid-off workers can now get a free month of ketamine-assisted therapy services to help with their mental health

Nue Life Health

Sherry Profile 3 crop

In this Episode

Sherry Rais

Sherry Rais, MSc, has helped dozens of startups, non-profit organizations, academic/research institutions, and small businesses raise funds, operate according to their mission and values, and implement processes that enhance their overall efficiency. Sherry believes in living and working in alignment with purpose and is currently focused on expanding access to psychedelic-assisted therapy to alleviate human suffering. Before this, Sherry consulted for over 10 years with the United Nations and World Bank, implementing cash transfer programs at the national level in over 35 countries. Sherry holds a Master’s Degree in Public Policy and Management from the London School of Economics and a Bachelor’s Degree in Psychology and International Development from McGill University. She also completed the Certificate in Psychedelic Therapies and Research from CIIS in 2021. In addition to being Enthea‘s CEO, she is the Executive Director of the Boston Psychedelic Research Group and the Grants Manager for CIIS.